Identifying and exploiting defects in the fanconi anemia/BRCA pathway in oncology

Translational Research

Volumn 160, Issue 3, 2012, Pages 178-197

  Stecklein, Shane R ^a   Jensen, Roy A ^a  

^a UNIVERSITY OF KANSAS CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CISPLATIN; CURCUMIN; CYCLOPHOSPHAMIDE; DNA; EPIRUBICIN; FANCONI ANEMIA PROTEIN; GEMCITABINE; LAPATINIB; METHOTREXATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PLATINUM; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CYTOTOXICITY; DNA REPAIR; FANCONI ANEMIA; GENE MUTATION; GENE TARGETING; GENETIC RECOMBINATION; GENETIC STABILITY; GENOMIC INSTABILITY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HOMOLOGOUS RECOMBINATION; HUMAN; IONIZING RADIATION; LETHALITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CROSS LINKING; PROTEIN FUNCTION; REVIEW;

EID: 84865720442     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2012.01.022     Document Type: Review

References (121)

1. A.D. D'Andrea Susceptibility pathways in Fanconi's anemia and breast cancer N Engl J Med 362 2010 1909 1919
2. W. Wang Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins Nat Rev Genet 8 2007 735 748 (Pubitemid 47429206)
3. D.I. Kutler, and A.D. Auerbach Fanconi anemia in Ashkenazi Jews Fam Cancer 3 2004 241 248
4. B.P. Alter, M.H. Greene, I. Velazquez, and P.S. Rosenberg Cancer in Fanconi anemia Blood 101 2003 2072
5. D.I. Kutler, B. Singh, and J. Satagopan A 20-year perspective on the International Fanconi Anemia Registry (IFAR) Blood 101 2003 1249 1256 (Pubitemid 36182492)
6. E. Gluckman, A.D. Auerbach, and M.M. Horowitz Bone marrow transplantation for Fanconi anemia Blood 86 1995 2856 2862
7. E. Gluckman, and J.E. Wagner Hematopoietic stem cell transplantation in childhood inherited bone marrow failure syndrome Bone Marrow Transplant 41 2008 127 132 (Pubitemid 351188909)
8. A. Antoniou, P.D. Pharoah, and S. Narod Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies Am J Hum Genet 72 2003 1117 1130 (Pubitemid 36530000)
9. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium J Natl Cancer Inst 91 1999 1310 1316
10. N. Rahman, S. Seal, and D. Thompson PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene Nat Genet 39 2007 165 167 (Pubitemid 46184346)
11. S. Seal, D. Thompson, and A. Renwick Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles Nat Genet 38 2006 1239 1241 (Pubitemid 44646283)
12. W.S. Rubinstein Hereditary breast cancer in Jews Fam Cancer 3 2004 249 257
13. A.C. Antoniou, P.D. Pharoah, and S. Narod Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies J Med Genet 42 2005 602 603 (Pubitemid 40993838)
14. J.E. Armes, L. Trute, and D. White Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study Cancer Res 59 1999 2011 2017 (Pubitemid 29186179)
15. S.R. Lakhani, M.J. Van De Vijver, and J. Jacquemier The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2 J Clin Oncol 20 2002 2310 2318 (Pubitemid 34441658)
16. S.R. Lakhani, J.S. Reis-Filho, and L. Fulford Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype Clin Cancer Res 11 2005 5175 5180 (Pubitemid 41003703)
17. L.A. Quenneville, K.A. Phillips, and H. Ozcelik HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry Cancer 95 2002 2068 2075 (Pubitemid 35253367)
18. J. Palacios, E. Honrado, and A. Osorio Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers Breast Cancer Res Treat 90 2005 5 14 (Pubitemid 40486996)
19. T. Sorlie, R. Tibshirani, and J. Parker Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 100 2003 8418 8423 (Pubitemid 36842560)
20. L.C. Verhoog, C.T. Brekelmans, and C. Seynaeve Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1 Lancet 351 1998 316 321 (Pubitemid 28052696)
21. T. Agurs-Collins, B.K. Dunn, D. Browne, K.A. Johnson, and R. Lubet Epidemiology of health disparities in relation to the biology of estrogen receptor-negative breast cancer Semin Oncol 37 2010 384 401
22. N.C. Turner, J.S. Reis-Filho, and A.M. Russell BRCA1 dysfunction in sporadic basal-like breast cancer Oncogene 26 2007 2126 2132 (Pubitemid 46514749)
23. W.D. Foulkes BRCA1 functions as a breast stem cell regulator J Med Genet 41 2004 1 5 (Pubitemid 38125677)
24. D. Tkocz, N.T. Crawford, and N.E. Buckley BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers Oncogene 2011 [Epub ahead of print]
25. T.A. Proia, P.J. Keller, and P.B. Gupta Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate Cell Stem Cell 8 2011 149 163
26. A.D. Auerbach, and S.R. Wolman Susceptibility of Fanconi's anaemia fibroblasts to chromosome damage by carcinogens Nature 261 1976 494 496
27. C.B. Bridges The origin of variation Amer Nat 56 1922 51 63
28. I. Cass, R.L. Baldwin, T. Varkey, R. Moslehi, S.A. Narod, and B.Y. Karlan Improved survival in women with BRCA-associated ovarian carcinoma Cancer 97 2003 2187 2195 (Pubitemid 36444059)
29. P.O. Chappuis, J. Goffin, and N. Wong A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer J Med Genet 39 2002 608 610 (Pubitemid 34864568)
30. H. Farmer, N. McCabe, and C.J. Lord Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 2005 917 921 (Pubitemid 40559006)
31. N. McCabe, N.C. Turner, and C.J. Lord Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition Cancer Res 66 2006 8109 8115 (Pubitemid 44299177)
32. P.C. Fong, D.S. Boss, and T.A. Yap Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 2009 123 134
33. P.C. Fong, T.A. Yap, and D.S. Boss Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2010 2512 2519
34. M.W. Audeh, J. Carmichael, and R.T. Penson Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Lancet 376 2010 245 251
35. A. Tutt, M. Robson, and J.E. Garber Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 376 2010 235 244
36. J. O'Shaughnessy, C. Osborne, and J.E. Pippen Iniparib plus chemotherapy in metastatic triple-negative breast cancer N Engl J Med 364 2011 205 214
37. M. Guha PARP inhibitors stumble in breast cancer Nat Biotechnol 29 2011 373 374
38. B.T. Hennessy, K.M. Timms, and M.S. Carey Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer J Clin Oncol 28 2010 3570 3576
39. P.A. Konstantinopoulos, D. Spentzos, and B.Y. Karlan Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer J Clin Oncol 28 2010 3555 3561
40. J.E. Quinn, C.R. James, and G.E. Stewart BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy Clin Cancer Res 13 2007 7413 7420
41. E.M. Swisher, R.M. Gonzalez, and T. Taniguchi Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas Mol Cancer 8 2009 48
42. J.M. Teodoridis, J. Hall, and S. Marsh CpG island methylation of DNA damage response genes in advanced ovarian cancer Cancer Res 65 2005 8961 8967 (Pubitemid 41377387)
43. J. Weberpals, K. Garbuio, and A. O'Brien The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer Int J Cancer 124 2009 806 815
44. S.A. Martin, A. McCarthy, and L.J. Barber Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2 EMBO Mol Med 1 2009 323 337
45. S.R. Stecklein, R.A. Jensen, and A. Pal Genetic and epigenetic signatures of breast cancer subtypes Front Biosci (Elite Ed) 4 2012 934 949
46. M. Robson, T. Gilewski, and B. Haas BRCA-associated breast cancer in young women J Clin Oncol 16 1998 1642 1649
47. O.T. Johannsson, J. Ranstam, A. Borg, and H. Olsson Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden J Clin Oncol 16 1998 397 404 (Pubitemid 28135579)
48. D.K. Gaffney, R.M. Brohet, and C.M. Lewis Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations Radiother Oncol 47 1998 129 136 (Pubitemid 28275921)
49. Y. Ansquer, C. Gautier, A. Fourquet, B. Asselain, and D. Stoppa-Lyonnet Survival in early-onset BRCA1 breast-cancer patients. Institut Curie Breast Cancer Group Lancet 352 1998 541 (Pubitemid 28372229)
50. P.O. Chappuis, L. Kapusta, and L.R. Begin Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer J Clin Oncol 18 2000 4045 4052 (Pubitemid 32038396)
51. D. Stoppa-Lyonnet, Y. Ansquer, and H. Dreyfus Familial invasive breast cancers: worse outcome related to BRCA1 mutations J Clin Oncol 18 2000 4053 4059 (Pubitemid 32038397)
52. P.O. Chappuis, J. Goffin, and N. Hamel Good response to chemotherapy (CT) and hormonotherapy (HT) in patients with BRCA1-related breast cancer (BRCA1-BC) (abstract) Hum Genet Suppl 69 2011 249
53. L. Bordeleau, S. Panchal, and P. Goodwin Prognosis of BRCA-associated breast cancer: a summary of evidence Breast Cancer Res Treat 119 2010 13 24
54. H. Asakawa, H. Koizumi, and A. Koike Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins Breast Cancer Res 12 2010 R17
55. M.E. Thompson, R.A. Jensen, and P.S. Obermiller Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression Nat Genet 9 1995 444 450
56. A.I. Garcia, M. Buisson, and P. Bertrand Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers EMBO Mol Med 3 2011 279 290
57. P. Moskwa, F.M. Buffa, and Y. Pan miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors Mol Cell 41 2011 210 220
58. M. Wei, J. Xu, and J. Dignam Estrogen receptor α, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers Breast Cancer Res Treat 111 2008 113 120 (Pubitemid 352009235)
59. E. Tokunaga, S. Okada, and H. Kitao Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer Breast Cancer 18 2011 120 123
60. A. Potapova, A.M. Hoffman, A.K. Godwin, T. Al-Saleem, and P. Cairns Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer Cancer Res 68 2008 998 1002 (Pubitemid 351272217)
61. S. Sinha, R.K. Singh, N. Alam, A. Roy, S. Roychoudhury, and C.K. Panda Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: pathological significance in early- and late-onset breast carcinoma Mol Cancer 7 2008 84
62. P. van der Groep, M. Hoelzel, H. Buerger, H. Joenje, J.P. de Winter, and P.J. van Diest Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer Breast Cancer Res Treat 107 2008 41 47 (Pubitemid 350179594)
63. K.M. Tewey, T.C. Rowe, L. Yang, B.D. Halligan, and L.F. Liu Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II Science 226 1984 466 468 (Pubitemid 14012819)
64. M. Shrivastav, L.P. De Haro, and J.A. Nickoloff Regulation of DNA double-strand break repair pathway choice Cell Res 18 2008 134 147
65. D.M. Spencer, R.A. Bilardi, and T.H. Koch DNA repair in response to anthracycline-DNA adducts: a role for both homologous recombination and nucleotide excision repair Mutat Res 638 2008 110 121
66. A. Eastman Reevaluation of interaction of cis-dichloro(ethylenediamine) platinum(II) with DNA Biochemistry 25 1986 3912 3915 (Pubitemid 16042519)
67. A.J. Deans, and S.C. West DNA interstrand crosslink repair and cancer Nat Rev Cancer 11 2011 467 480
68. S.C. Rubin, I. Benjamin, and K. Behbakht Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1 N Engl J Med 335 1996 1413 1416 (Pubitemid 26382501)
69. R.E. Buller, M.S. Shahin, J.P. Geisler, M. Zogg, B.R. De Young, and C.S. Davis Failure of BRCA1 dysfunction to alter ovarian cancer survival Clin Cancer Res 8 2002 1196 1202 (Pubitemid 34520421)
70. M.P. Radosa, N. Hafner, and O. Camara Loss of BRCA1 protein expression as indicator of the BRCAness phenotype is associated with favorable overall survival after complete resection of sporadic ovarian cancer Int J Gynecol Cancer 21 2011 1399 1406
71. R.A. Lacour, S.N. Westin, and L.A. Meyer Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations Gynecol Oncol 121 2011 358 363
72. P.M. Vencken, M. Kriege, and D. Hoogwerf Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients Ann Oncol 22 2011 1346 1352
73. D.J. Gallagher, J.A. Konner, and K.M. Bell-McGuinn Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity Ann Oncol 22 2011 1127 1132
74. D.S. Tan, C. Rothermundt, and K. Thomas "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations J Clin Oncol 26 2008 5530 5536
75. T. Taniguchi, M. Tischkowitz, and N. Ameziane Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors Nat Med 9 2003 568 574 (Pubitemid 36597103)
76. Z. Wang, M. Li, S. Lu, Y. Zhang, and H. Wang Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway Cancer Biol Ther 5 2006 256 260
77. S.L. Lim, P. Smith, and N. Syed Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer Br J Cancer 98 2008 1452 1456 (Pubitemid 351543586)
78. V.S. Dhillon, M. Shahid, and S.A. Husain CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin Mol Cancer 3 2004 33
79. J.W. Chiang, B.Y. Karlan, L. Cass, and R.L. Baldwin BRCA1 promoter methylation predicts adverse ovarian cancer prognosis Gynecol Oncol 101 2006 403 410 (Pubitemid 43729975)
80. L. Fachal, A. Gomez-Caamano, and C. Celeiro-Munoz BRCA1 mutations do not increase prostate cancer risk: results from a meta-analysis including new data Prostate 71 2011 1768 1779
81. N. Bednarz, E. Eltze, and A. Semjonow BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood Clin Cancer Res 16 2010 3340 3348
82. M. Fiorentino, G. Judson, and K. Penney Immunohistochemical expression of BRCA1 and lethal prostate cancer Cancer Res 70 2010 3136 3139
83. C.J. van Asperen, R.M. Brohet, and E.J. Meijers-Heijboer Cancer risks in BRCA2 families: estimates for sites other than breast and ovary J Med Genet 42 2005 711 719 (Pubitemid 41306062)
84. A. Mitra, C. Fisher, and C.S. Foster Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype Br J Cancer 98 2008 502 507 (Pubitemid 351161242)
85. S.M. Edwards, D.G. Evans, and Q. Hope Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis Br J Cancer 103 2010 918 924
86. L. Tryggvadottir, L. Vidarsdottir, and T. Thorgeirsson Prostate cancer progression and survival in BRCA2 mutation carriers J Natl Cancer Inst 99 2007 929 935 (Pubitemid 47073499)
87. P.S. Rosenberg, B.P. Alter, and W. Ebell Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry Haematologica 93 2008 511 517 (Pubitemid 351536378)
88. P.S. Rosenberg, G. Socie, B.P. Alter, and E. Gluckman Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants Blood 105 2005 67 73 (Pubitemid 40053065)
89. P. Guardiola, G. Socie, and X. Li Acute graft-versus-host disease in patients with Fanconi anemia or acquired aplastic anemia undergoing bone marrow transplantation from HLA-identical sibling donors: risk factors and influence on outcome Blood 103 2004 73 77 (Pubitemid 38029920)
90. G. Socie, A. Devergie, and T. Girinski Transplantation for Fanconi's anaemia: long-term follow-up of fifty patients transplanted from a sibling donor after low-dose cyclophosphamide and thoraco-abdominal irradiation for conditioning Br J Haematol 103 1998 249 255 (Pubitemid 28470827)
91. C.J. Marsit, M. Liu, H.H. Nelson, M. Posner, M. Suzuki, and K.T. Kelsey Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival Oncogene 23 2004 1000 1004 (Pubitemid 38250946)
92. N. Ameziane, F. Chen, C.R. Leemans, R.H. Brakenhoff, and H. Joenje No evidence for FANCF gene silencing in head-and-neck squamous cell carcinomas Cell Oncol 31 2009 53 56
93. M. Szaumkessel, J. Richter, and M. Giefing Pyrosequencing-based DNA methylation profiling of Fanconi anemia/BRCA pathway genes in laryngeal squamous cell carcinoma Int J Oncol 39 2011 505 514
94. Cancer Facts & Figures 2010. American Cancer Society, 2010.
95. H.S. Evans, C.M. Lewis, D. Robinson, C.M. Bell, H. Moller, and S.V. Hodgson Incidence of multiple primary cancers in a cohort of women diagnosed with breast cancer in southeast England Br J Cancer 84 2001 435 440 (Pubitemid 32154442)
96. J.P. Struewing, P. Hartge, and S. Wacholder The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews N Engl J Med 336 1997 1401 1408 (Pubitemid 27208598)
97. M. Taron, R. Rosell, and E. Felip BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer Hum Mol Genet 13 2004 2443 2449 (Pubitemid 39377848)
98. R. Bartolucci, J. Wei, and J.J. Sanchez XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression Clin Lung Cancer 10 2009 47 52
99. L. Wang, J. Wei, and X. Qian ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel BMC Cancer 8 2008 97
100. I. Boukovinas, C. Papadaki, and P. Mendez Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients PLoS One 3 2008 e3695
101. E.P. Rogakou, D.R. Pilch, A.H. Orr, V.S. Ivanova, and W.M. Bonner DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139 J Biol Chem 273 1998 5858 5868 (Pubitemid 28124064)
102. P.L. Olive, and J.P. Banath Kinetics of H2AX phosphorylation after exposure to cisplatin Cytometry B Clin Cytom 76 2009 79 90
103. J.P. Banath, S.H. Macphail, and P.L. Olive Radiation sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell lines Cancer Res 64 2004 7144 7149 (Pubitemid 39331029)
104. H. Willers, L.A. Kachnic, and C.M. Luo Biomarkers and mechanisms of FANCD2 function J Biomed Biotechnol 2008 2008 821529
105. H. Willers, A.G. Taghian, C.M. Luo, A. Treszezamsky, D.C. Sgroi, and S.N. Powell Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies Mol Cancer Res 7 2009 1304 1309
106. N.C. Turner, and J.S. Reis-Filho Basal-like breast cancer and the BRCA1 phenotype Oncogene 25 2006 5846 5853 (Pubitemid 44453440)
107. M. Graeser, A. McCarthy, and C.J. Lord A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer Clin Cancer Res 16 2010 6159 6168
108. P. Wynne, C. Newton, J.A. Ledermann, A. Olaitan, T.A. Mould, and J.A. Hartley Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy Br J Cancer 97 2007 927 933 (Pubitemid 47519316)
109. M. Berwick, and P. Vineis Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review J Natl Cancer Inst 92 2000 874 897 (Pubitemid 30429188)
110. S.L. Edwards, R. Brough, and C.J. Lord Resistance to therapy caused by intragenic deletion in BRCA2 Nature 451 2008 1111 1115 (Pubitemid 351317441)
111. W. Sakai, E.M. Swisher, and B.Y. Karlan Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers Nature 451 2008 1116 1120 (Pubitemid 351317449)
112. E.M. Swisher, W. Sakai, B.Y. Karlan, K. Wurz, N. Urban, and T. Taniguchi Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance Cancer Res 68 2008 2581 2586 (Pubitemid 351556255)
113. W. Sakai, E.M. Swisher, and C. Jacquemont Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma Cancer Res 69 2009 6381 6386
114. B. Norquist, K.A. Wurz, and C.C. Pennil Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas J Clin Oncol 29 2011 3008 3015
115. M. Ferrer, J.P. de Winter, and D.C. Mastenbroek Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA Cancer Gene Ther 11 2004 539 546 (Pubitemid 39079492)
116. D. Chirnomas, T. Taniguchi, and M. de la Vega Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway Mol Cancer Ther 5 2006 952 961 (Pubitemid 43724595)
117. M. Noguchi, D. Yu, and R. Hirayama Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin Biochem Biophys Res Commun 351 2006 658 663 (Pubitemid 44708858)
118. I. Landais, A. Sobeck, S. Stone, A. LaChapelle, and M.E. Hoatlin A novel cell-free screen identifies a potent inhibitor of the Fanconi anemia pathway Int J Cancer 124 2009 783 792
119. Y. Wu, D. Bhattacharyya, and C.L. King Solution structures of a DNA dodecamer duplex with and without a cisplatin 1,2-d(GG) intrastrand cross-link: comparison with the same DNA duplex containing an oxaliplatin 1,2-d(GG) intrastrand cross-link Biochemistry 46 2007 6477 6487 (Pubitemid 46876489)
120. A. Gelasco, and S.J. Lippard NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin Biochemistry 37 1998 9230 9239 (Pubitemid 28307676)
121. F. Coste, J.M. Malinge, and L. Serre Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63 A resolution: hydration at the platinated site Nucleic Acids Res 27 1999 1837 1846 (Pubitemid 29209625)